UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): March 2, 2020
(Exact Name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction of
Incorporation)
Delaware | ||||
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||
(Address of Principal Executive Offices, and Zip Code)
Registrant’s Telephone Number, Including Area Code
(Former Name or Former Address, if Changed Since Last Report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On March 2, 2020, Amicus Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal year ended December 31, 2019. A copy of this press release is attached hereto as Exhibit 99.1. The Company will host a conference call and webcast on March 2, 2020 to discuss its full year results of operations. A copy of the conference call presentation materials is attached hereto as Exhibit 99.2. Both exhibits are incorporated herein by reference.
In accordance with General Instruction B.2. of Form 8-K, the information in this Current Report on Form 8-K and the Exhibits shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits:
Exhibit No. | Description |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
Signature Page
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
AMICUS THERAPEUTICS, INC. | |
Date: March 2, 2020 | By: /s/ Ellen S. Rosenberg |
Name: Ellen S. Rosenberg | |
Title: Chief Legal Officer and Corporate Secretary | |
Amicus Therapeutics Announces Full-Year 2019 Financial Results and 2020 Corporate Updates
2019 Galafold Revenue Nearly Doubled to $182.2M
On Track to Achieve 2020 Revenue Guidance of $250M-$260M
Focused on Pompe Phase 3 PROPEL Study, Manufacturing to Support 2021 BLA and MAA, and Accelerating Expanded Access Program for Infantile-Onset Patients
Advancing Industry-Leading Rare Disease Gene Therapy Portfolio
Strong Balance Sheet with $450M+ Cash – Cash Runway Well into 2022
Conference Call and Webcast Today at 8:30 a.m. ET
CRANBURY, NJ, March 2, 2020 – Amicus Therapeutics (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced financial results for the full-year ended December 31, 2019. The Company also summarized recent program updates and reiterated its full-year 2020 guidance.
Corporate Highlights for Full-Year 2019 and Year-to-Date 2020
• | Galafold® (migalastat), the first oral treatment option for people living with Fabry and who have an amenable variant, revenue grew from $91.2 million in full-year 2018 to $182.2 million in full-year 2019, exceeding the high end of the full-year 2019 guidance range of $170 million to $180 million. Over the course of 2019, Amicus received key marketing authorizations around the globe, including Argentina, Brazil, Colombia and Taiwan. |
• | Global Phase 3 PROPEL clinical trial of AT-GAA in late-onset Pompe disease exceeded enrollment and inventory build remains on track. As previously announced, 59 clinical sites enrolled 123 participants globally in the Phase 3 PROPEL study. Process performance qualification (PPQ) runs nearing successful completion with key strategic partner, WuXi Biologics, and will serve as the foundation for the Chemistry, Manufacturing, and Control (CMC) module for a biologics license application (BLA) submission. |
• | The Company plans to apply for and initiate a rolling BLA for AT-GAA, completing final submission in the first half of 2021. |
• | Focus on an Expanded Access Program for infantile-onset Pompe patients. Amicus intends to offer an expanded access program for infantile-onset patients. |
• | Presented positive interim results in ongoing Phase 1/2 clinical study for CLN6 Batten disease. Data on motor, language, seizure and vision sub scores suggest stabilization of these individual components in most patients, in particular those children treated at a younger age. |
• | Amicus continues to carefully manage expenses and investments, while executing on the Galafold launch and advancing development programs. The current cash position is expected to fund ongoing operations well into 2022. |
2020 Key Strategic Priorities
• | Achieve $250 million to $260 million of global product revenue for Galafold |
• | Complete Pompe Phase 3 PROPEL study, enroll pediatric studies and advance manufacturing to support 2021 BLA and MAA |
• | Advance clinical development, manufacturing and regulatory discussions for CLN6 and CLN3 Batten programs |
• | Progress Pompe gene therapy towards IND and disclose up to two additional IND candidates |
• | Maintain strong financial position |
John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc. stated, “Amicus has made great strides in our continued evolution as a leading global rare disease biotechnology company. We are on track and well-capitalized to achieve all our 2020 key strategic priorities including our global Fabry launch, Pompe late-stage development program, and gene therapy pipeline. With a very successful, commercial product in Fabry disease, a late stage program with Breakthrough Therapy Designation in late onset Pompe disease and 14 gene therapy programs for rare diseases in development, including two in the clinic, we are now, strongly positioned to achieve our vision of delivering groundbreaking new medicines and hopefully one day cures for people living with rare metabolic diseases.”
Full-Year 2019 Financial Results
• | Total revenue in the full-year 2019 was $182.2 million, an increase from total revenue of $91.2 million in the full-year 2018. |
• | Cash, cash equivalents, and marketable securities totaled $452.7 million at December 31, 2019, compared to $504.2 million at December 31, 2018. |
• | Total GAAP operating expenses were $464.3 million for the full-year 2019, compared to $405.6 million in the full-year 2018. Operating expenses reflecting increased investments in the Galafold launch, Pompe program, and gene therapy pipeline. |
• | Total non-GAAP operating expenses of $411.8 million for the full-year 2019 increased as compared to $268.8 million for the full-year 2018, reflecting continued investments in the Galafold launch, Pompe program, and gene therapy pipeline. Non-GAAP operating expenses came in at the lower end of the guidance range of $410 million to $420 million. Full reconciliation of GAAP results to the Company’s non-GAAP adjusted measures for all reporting periods appear in the tables to this press release. |
• | Net loss was $356.4 million, or $1.48 per share, compared to a net loss of $349.0 million, or $1.88 per share, for the full-year 2018. |
2020 Financial Guidance
• | For the full-year 2020, the Company anticipates total Galafold revenue of $250 million to $260 million based on the average exchange rates for 2019. |
• | Non-GAAP operating expense guidance for the full-year 2020 is $410 million to $420 million, driven by continued investment in the global Galafold launch, AT-GAA clinical studies, and advancing our gene therapy pipeline. A reconciliation of the differences between the non-GAAP expectation and the corresponding GAAP measure is not available without unreasonable effort due to high variability, complexity and low visibility as to the items that would be excluded from the GAAP measure. |
• | Cash, cash equivalents, and marketable securities totaled $452.7 million at December 31, 2019. The current cash position is anticipated to fund ongoing operations well into 2022. |
Anticipated 2020 Milestones by Program
Amicus previously announced 2020 program milestones in early January 2020. All anticipated milestones remain on track as follows:
Galafold (migalastat) Oral Precision Medicine for Fabry Disease
• | On track to meet full-year 2020 revenue guidance range of $250 million to $260 million |
• | Registry and other Phase 4 supportive studies underway |
AT-GAA for Pompe Disease
• | Plans to apply for and initiate a Rolling Biologics License Application (BLA) for AT-GAA in 2020, with addition of full clinical results in 1H2021 to support full approval under Fast Track Designation |
• | Retrospective natural history study data in approximately 100 ERT-treated Pompe patients |
• | Additional supportive studies, including an open-label study in 12 to 18-year-old patients |
Gene Therapy Portfolio
• | Dose additional patients in CLN6 Phase 1/2 study and plan to advance regulatory discussions to finalize clinical and regulatory path |
• | Initiate long-term follow-up of initial participants in the CLN6 Phase 1/2 study in 1H2020 to obtain long-term safety and efficacy data |
• | Plan to advance regulatory discussions to finalize clinical and regulatory path in CLN3 |
• | Report initial data on patients enrolled in CLN3 Phase 1/2 study |
• | Complete IND-enabling toxicology work in Pompe disease and progress towards IND |
• | Additional preclinical data expected in multiple programs |
• | Disclose up to two additional IND candidates |
• | Manufacturing advancements across portfolio |
Conference Call and Webcast
Amicus Therapeutics will host a conference call and audio webcast today, March 2, 2020, at 8:30 a.m. ET to discuss the full-year 2019 financial results and corporate updates. Interested participants and investors may access the conference call by dialing 877-303-5859 (U.S./Canada) or 678-224-7784 (international), conference ID: 2782337.
A live audio webcast can also be accessed via the Investors section of the Amicus Therapeutics corporate website at http://ir.amicusrx.com/, and will be archived for 30 days. Web participants are encouraged to register on the website 15 minutes prior to the start of the call. A replay of the call will be available for seven days beginning at 11:30 a.m. ET on March 2, 2020. Access numbers for this replay are 855-859-2056 (U.S./Canada) and 404-537-3406 (international); conference ID: 2782337.
About Galafold
Galafold® (migalastat) 123 mg capsules is an oral pharmacological chaperone of alpha-Galactosidase A (alpha-Gal A) for the treatment of Fabry disease in adults who have amenable GLA variants. In these patients, Galafold works by stabilizing the body’s own dysfunctional enzyme so that it can clear the accumulation of disease substrate. Globally, Amicus Therapeutics estimates that approximately 35 to 50 percent of Fabry patients may have amenable GLA variants, though amenability rates within this range vary by geography. Galafold is approved in over 40 countries around the world, including the U.S., EU, U.K, Japan and others.
Galafold® (migalastat) 123 mg capsules is an oral pharmacological chaperone of alpha-Galactosidase A (alpha-Gal A) for the treatment of Fabry disease in adults who have amenable GLA variants. In these patients, Galafold works by stabilizing the body’s own dysfunctional enzyme so that it can clear the accumulation of disease substrate. Globally, Amicus Therapeutics estimates that approximately 35 to 50 percent of Fabry patients may have amenable GLA variants, though amenability rates within this range vary by geography. Galafold is approved in over 40 countries around the world, including the U.S., EU, U.K, Japan and others.
U.S. Indications and Usage
Galafold is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data.
Galafold is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data.
This indication is approved under accelerated approval based on reduction in kidney interstitial capillary cell globotriaosylceramide (KIC GL-3) substrate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
U.S. Important Safety Information
Adverse Reactions
The most common adverse reactions reported with Galafold (≥10%) were headache, nasopharyngitis, urinary tract infection, nausea and pyrexia.
The most common adverse reactions reported with Galafold (≥10%) were headache, nasopharyngitis, urinary tract infection, nausea and pyrexia.
Use in Specific Populations
There is insufficient clinical data on Galafold use in pregnant women to inform a drug-associated risk for major birth defects and miscarriage. Advise women of the potential risk to a fetus.
There is insufficient clinical data on Galafold use in pregnant women to inform a drug-associated risk for major birth defects and miscarriage. Advise women of the potential risk to a fetus.
It is not known if Galafold is present in human milk. Therefore, the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Galafold and any potential adverse effects on the breastfed child from Galafold or from the underlying maternal condition.
Galafold is not recommended for use in patients with severe renal impairment or end-stage renal disease requiring dialysis.
The safety and effectiveness of Galafold have not been established in pediatric patients.
To report Suspected Adverse Reactions, contact Amicus Therapeutics at 1-877-4AMICUS or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
For additional information about Galafold, including the full U.S. Prescribing Information, please visit https://www.amicusrx.com/pi/Galafold.pdf.
E.U. and U.K. Important Safety Information
Treatment with Galafold should be initiated and supervised by specialists experienced in the diagnosis and treatment of Fabry disease. Galafold is not recommended for use in patients with a nonamenable mutation.
• | Galafold is not intended for concomitant use with enzyme replacement therapy. |
• | Galafold is not recommended for use in patients with Fabry disease who have severe renal impairment (<30 mL/min/1.73 m2). The safety and efficacy of Galafold in children 0–15 years of age have not yet been established. |
• | No dosage adjustments are required in patients with hepatic impairment or in the elderly population. |
• | There is very limited experience with the use of this medicine in pregnant women. If you are pregnant, think you may be pregnant, or are planning to have a baby, do not take this medicine until you have checked with your doctor, pharmacist, or nurse. |
• | While taking Galafold, effective birth control should be used. It is not known whether Galafold is excreted in human milk. |
• | Contraindications to Galafold include hypersensitivity to the active substance or to any of the excipients listed in the PRESCRIBING INFORMATION. |
• | It is advised to periodically monitor renal function, echocardiographic parameters and biochemical markers (every 6 months) in patients initiated on Galafold or switched to Galafold. |
• | OVERDOSE: General medical care is recommended in the case of Galafold overdose. |
• | The most common adverse reaction reported was headache, which was experienced by approximately 10% of patients who received Galafold. For a complete list of adverse reactions, please review the SUMMARY OF PRODUCT CHARACTERISTICS. |
• | Call your doctor for medical advice about side effects. |
For further important safety information for Galafold, including posology and method of administration, special warnings, drug interactions and adverse drug reactions, please see the European SmPC for Galafold available from the EMA website at www.ema.europa.eu.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of
cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the company’s website at www.amicusrx.com, and follow on Twitter and LinkedIn.
Non-GAAP Financial Measures
In addition to financial information prepared in accordance with U.S. GAAP, this press release also contains adjusted financial measures that we believe provide investors and management with supplemental information relating to operating performance and trends that facilitate comparisons between periods and with respect to projected information. These adjusted financial measures are non-GAAP measures and should be considered in addition to, but not as a substitute for, the information prepared in accordance with U.S. GAAP. We typically exclude certain GAAP items that management does not believe affect our basic operations and that do not meet the GAAP definition of unusual or non-recurring items. Other companies may define these measures in different ways. Full reconciliations of GAAP results to the comparable non-GAAP measures for the reported periods appear in the financial tables section of this press release. When we provide our expectation for non-GAAP operating expenses on a forward-looking basis, a reconciliation of the differences between the non-GAAP expectation and the corresponding GAAP measure generally is not available without unreasonable effort due to potentially high variability, complexity and low visibility as to the items that would be excluded from the GAAP measure in the relevant future period, such as unusual gains or losses. The variability of the excluded items may have a significant, and potentially unpredictable, impact on our future GAAP results.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and clinical trials, the prospects and timing of the potential regulatory approval of our product candidates, commercialization plans, manufacturing and supply plans, financing plans, and the projected revenues and cash position for the Company. The inclusion of forward-looking statements should not be regarded as a representation by us that any of our plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong and can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the goals, progress, timing, and outcomes of discussions with regulatory authorities, and in particular the potential goals, progress, timing, and results of preclinical studies and clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in our business, including, without limitation: the potential that results of clinical or preclinical studies indicate that the product candidates are unsafe or ineffective; the potential that it may be difficult to enroll patients in our clinical trials; the potential that regulatory authorities, including the FDA, EMA, and PMDA, may not grant or may delay approval for our product candidates; the potential that we may not be successful in commercializing Galafold in Europe, Japan, the US and other geographies or our other product candidates if and when approved; the potential that preclinical and clinical studies could be delayed because we identify serious side effects or other safety issues; the potential that we may not be able to manufacture or supply sufficient clinical or commercial products; and the potential that we will need additional funding to complete all of our studies and manufacturing. Further, the results of earlier preclinical studies and/or clinical trials may not be predictive of future results. With respect to statements regarding projections of the Company's revenue and cash position, actual results may differ based on market factors and the Company's ability to execute its operational and budget plans. In addition, all forward-looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2019 to be filed today. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and we undertake no obligation to revise or update this news release to reflect events or circumstances after the date hereof.
CONTACTS:
Investors:
Andrew Faughnan
Director, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809
Media:
Christopher Byrne
Executive Director, Corporate Communications
cbyrne@amicusrx.com
(609) 662-2798
FOLD–G
TABLE 1
Amicus Therapeutics, Inc.
Consolidated Statements of Operations
(in thousands, except share and per share amounts)
Years Ended December 31, | ||||||||||||||
2019 | 2018 | 2017 | ||||||||||||
Net product sales | $ | 182,237 | $ | 91,245 | $ | 36,930 | ||||||||
Cost of goods sold | 21,963 | 14,404 | 6,236 | |||||||||||
Gross profit | 160,274 | 76,841 | 30,694 | |||||||||||
Operating expenses: | ||||||||||||||
Research and development | 286,378 | 270,902 | 149,310 | |||||||||||
Selling, general, and administrative | 169,861 | 127,200 | 88,671 | |||||||||||
Changes in fair value of contingent consideration payable | 3,297 | 3,300 | (234,322) | |||||||||||
Loss on impairment of assets | — | — | 465,427 | |||||||||||
Depreciation and amortization | 4,775 | 4,216 | 3,593 | |||||||||||
Total operating expenses | 464,311 | 405,618 | 472,679 | |||||||||||
Loss from operations | (304,037) | (328,777) | (441,985) | |||||||||||
Other income (expenses): | ||||||||||||||
Interest income | 10,249 | 10,461 | 4,096 | |||||||||||
Interest expense | (18,872) | (22,402) | (17,240) | |||||||||||
Loss on exchange of convertible notes | (40,624) | — | — | |||||||||||
Change in fair value of derivatives | — | (2,739) | — | |||||||||||
Other (expense) income | (2,626) | (5,632) | 6,008 | |||||||||||
Loss before income tax | (355,910) | (349,089) | (449,121) | |||||||||||
Income tax (expense) benefit | (478) | 94 | 165,119 | |||||||||||
Net loss attributable to common stockholders | $ | (356,388) | $ | (348,995) | $ | (284,002) | ||||||||
Net loss attributable to common stockholders per common share — basic and diluted | $ | (1.48) | $ | (1.88) | $ | (1.85) | ||||||||
Weighted-average common shares outstanding — basic and diluted | 240,421,001 | 185,790,021 | 153,355,144 | |||||||||||
TABLE 2
Amicus Therapeutics, Inc.
Consolidated Balance Sheets
(in thousands, except share and per share amounts)
December 31, | ||||||||
2019 | 2018 | |||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 142,837 | $ | 79,749 | ||||
Investments in marketable securities | 309,903 | 424,403 | ||||||
Accounts receivable | 33,284 | 21,962 | ||||||
Inventories | 14,041 | 8,390 | ||||||
Prepaid expenses and other current assets | 20,008 | 16,592 | ||||||
Total current assets | 520,073 | 551,096 | ||||||
Operating lease right-of-use assets, less accumulated amortization of $5,342 and $0 at December 31, 2019 and December 31, 2018, respectively | 33,315 | — | ||||||
Property and equipment, less accumulated depreciation of $17,604 and $15,671 at December 31, 2019 and December 31, 2018, respectively | 47,705 | 11,375 | ||||||
In-process research & development | 23,000 | 23,000 | ||||||
Goodwill | 197,797 | 197,797 | ||||||
Other non-current assets | 28,317 | 6,683 | ||||||
Total Assets | $ | 850,207 | $ | 789,951 | ||||
Liabilities and Stockholders' Equity | ||||||||
Current liabilities: | ||||||||
Accounts payable, accrued expenses, and other current liabilities | $ | 120,373 | $ | 80,625 | ||||
Deferred reimbursements | 1,250 | 5,500 | ||||||
Operating lease liabilities | 7,189 | — | ||||||
Total current liabilities | 128,812 | 86,125 | ||||||
Deferred reimbursements | 8,906 | 10,156 | ||||||
Convertible notes | 2,131 | 175,006 | ||||||
Senior secured term loan | 147,374 | 146,734 | ||||||
Contingent consideration payable | 22,681 | 19,700 | ||||||
Deferred income taxes | 5,051 | 6,465 | ||||||
Operating lease liabilities | 53,531 | — | ||||||
Other non-current liabilities | 5,296 | 2,853 | ||||||
Total Liabilities | 373,782 | 447,039 | ||||||
Commitments and contingencies | ||||||||
Stockholders' equity: | ||||||||
Common stock, $.01 par value, 500,000,000 shares authorized, 255,417,869 and 189,383,924 shares issued and outstanding at December 31, 2019 and December 31, 2018, respectively | 2,598 | 1,942 | ||||||
Additional paid-in capital | 2,227,225 | 1,740,061 | ||||||
Accumulated other comprehensive loss: | ||||||||
Foreign currency translation adjustment | 2,785 | 495 | ||||||
Unrealized gain (loss) on available-for securities | 40 | (427) | ||||||
Warrants | 12,387 | 13,063 | ||||||
Accumulated deficit | (1,768,610) | (1,412,222) | ||||||
Total stockholders' equity | 476,425 | 342,912 | ||||||
Total Liabilities and Stockholders' Equity | $ | 850,207 | $ | 789,951 | ||||
TABLE 3
Amicus Therapeutics, Inc.
Reconciliation of Non-GAAP Financial Measures
(in thousands)
Years Ended December 31, | ||||||||||||
2019 | 2018 | 2017 | ||||||||||
Total operating expenses - as reported GAAP | $ | 464,311 | $ | 405,618 | $472,679 | |||||||
Research and development: | ||||||||||||
Share-based compensation | 17,575 | 11,740 | 10,328 | |||||||||
Research and development asset acquisition expense | — | 100,000 | — | |||||||||
Selling, general and administrative: | ||||||||||||
Share-based compensation | 26,855 | 17,520 | 12,773 | |||||||||
Loss on impairment of assets | — | — | 465,427 | |||||||||
Changes in fair value of contingent consideration payable | 3,297 | 3,300 | (234,322) | |||||||||
Depreciation and amortization | 4,775 | 4,216 | 3,593 | |||||||||
Total operating expense adjustments to reported GAAP | 52,502 | 136,776 | 257,799 | |||||||||
Total operating expenses - as adjusted | $ | 411,809 | $ | 268,842 | $ | 214,880 | ||||||
2019 Financial Results Conference Call & Webcast March 2, 2020
Introduction 2 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and clinical trials, the prospects and timing of the potential regulatory approval of our product candidates, commercialization plans, manufacturing and supply plans, financing plans, and the projected revenues and cash position for the Company. The inclusion of forward-looking statements should not be regarded as a representation by us that any of our plans will be achieved. Any or all of the forward-looking statements in this presentation may turn out to be wrong and can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the goals, progress, timing, and outcomes of discussions with regulatory authorities, and in particular the potential goals, progress, timing, and results of preclinical studies and clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in our business, including, without limitation: the potential that results of clinical or preclinical studies indicate that the product candidates are unsafe or ineffective; the potential that it may be difficult to enroll patients in our clinical trials; the potential that regulatory authorities, including the FDA, EMA, and PMDA, may not grant or may delay approval for our product candidates; the potential that we may not be successful in commercializing Galafold in Europe, Japan, the US and other geographies or our other product candidates if and when approved; the potential that preclinical and clinical studies could be delayed because we identify serious side effects or other safety issues; the potential that we may not be able to manufacture or supply sufficient clinical or commercial products; and the potential that we will need additional funding to complete all of our studies and manufacturing. Further, the results of earlier preclinical studies and/or clinical trials may not be predictive of future results. In addition to financial information prepared in accordance with U.S. G A A P, this presentation also contains adjusted financial measures that we believe provide investors and management with supplemental information relating to operating performance and trends that facilitate comparisons between periods and with respect to projected information. These adjusted financial measures are non-GAAP measures and should be considered in addition to, but not as a substitute for, the information prepared in accordance with U.S. GAAP. With respect to statements regarding projections of the Company's revenue and cash position, actual results may differ based on market factors and the Company's ability to execute its operational and budget plans. In addition, all forward-looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2019 to be filed today. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and we undertake no obligation to revise or update this news release to reflect events or circumstances after the date hereof. In addition to financial information prepared in accordance with U.S. GAAP, this presentation also contains adjusted financial measures that we believe provide investors and management with supplemental information relating to operating performance and trends that facilitate comparisons between periods and with respect to projected information. These adjusted financial measures are non-GAAP measures and should be considered in addition to, but not as a substitute for, the information prepared in accordance with U.S. GAAP. We typically exclude certain GAAP items that management does not believe affect our basic operations and that do not meet the GAAP definition of unusual or non-recurring items. Other companies may define these measures in different ways. Full reconciliations of GAAP results to the comparable non-GAAP measures for the reported periods appear in the financial tables section of this presentation. When we provide our expectation for non-GAAP operating expenses on a forward-looking basis, a reconciliation of the differences between the non-GAAP expectation and the corresponding GAAP measure generally is not available without unreasonable effort due to potentially high variability, complexity and low visibility as to the items that would be excluded from the GAAP measure in the relevant future period, such as unusual gains or losses. The variability of the excluded items may have a significant, and potentially unpredictable, impact on our future GAAP results.
Introduction 3 A leading fully-integrated, global rare disease biotechnology company Gene Therapy World Class PLATFORM BIOLOGICS Protein Engineering Capabilities & Glycobiology AT-GAA EMPLOYEES Phase 3 in Robust R&D in 27 Countries Pompe Disease Engine Nearly 50+ Lysosomal GLOBAL Disorders and More Prevalent Rare Diseases $450M+ Two Clinical- COMMERCIAL Cash Stage Gene ORGANIZATION as of 12/31/19 Therapies
Introduction 4 Key Takeaways Recent successes across our science, clinical, regulatory and commercial efforts position us for the future Galafold Continues AT-GAA for Pompe Portfolio of Gene Strong Financial Strong Launch Advances Toward Therapy Programs Outlook with Current Performance & Approval as “Crown and Technologies Cash Well into 2022 Cornerstone of Jewel” of Amicus Provides Foundation Amicus Success Portfolio for Future
Introduction 5 2020 Key Strategic Priorities 1 Achieve global product revenue for Galafold of $250M-$260M Complete Pompe Phase 3 PROPEL study, enroll pediatric studies 2 and advance manufacturing to support 2021 BLA and MAA Advance clinical development, manufacturing and regulatory 3 discussions for CLN6 and CLN3 Batten programs Progress Pompe gene therapy towards IND and disclose up to 4 two additional IND candidates 5 Maintain strong financial position
Galafold® (migalastat) Global Launch… …taking a leadership role in the treatment of Fabry disease “We push ideas as far and as fast as possible” - Amicus Belief Statement
Galafold: Precision Medicine for Fabry Disease 7 Galafold Snapshot (as of December 31, 2019) Galafold is the cornerstone of Amicus’ success. It is an orally delivered small molecule precision medicine with a unique mechanism of action for Fabry patients with amenable variants that replaces the need for intravenously delivered enzyme replacement therapy One of the Most Successful $182M FY19 Galafold $ Rare Disease Launches Revenue 250M-260M FY20 Global Galafold Rev. Guidance Geographic Expansion in 2019 Including Argentina, Brazil, Colombia, Taiwan 348 Amenable Variants 40+ in U.S. Label Countries with Regulatory Approvals: Including U.S., EU, U.K., Galafold is indicated for adults with a confirmed diagnosis of Fabry Disease and an amenable mutation/variant. The most common adverse reactions reported with Galafold (≥10%) were headache, Japan, and Other nasopharyngitis, urinary tract infection, nausea and pyrexia. For additional information about Galafold, including the full U.S. Prescribing Information, please visit https://www.amicusrx.com/pi/Galafold.pdf. For further important safety information for Galafold, including posology and method of administration, special warnings, drug interactions and adverse drug reactions, please see the European SmPC for Countries Galafold available from the EMA website at www.ema.europa.eu.
Galafold: Precision Medicine for Fabry Disease 8 2019 Galafold Success Strong full-year revenue performance of $182M, exceeding guidance of $170M-$180M Quarterly Galafold Sales Year-over-Year Galafold Sales Growth 60.0 $55M 50.0 $49M -5% $44M 40.0 +105% $34M 30.0 $182M 20.0 $91M 10.0 0.0 1Q19 2Q19 3Q19 4Q19 FY18 Operational Growth FX Impact FY19 FY18 vs FY19
Galafold: Precision Medicine for Fabry Disease 9 Galafold Growth Trajectory Galafold is on track to generate $1B+ in projected cumulative revenues from 2020-2022 and is on an anticipated path to $500M+ in annual sales in 2023 and $1B+ annual sales at peak $500M+ $1B Annual Revenue $250M- $91M $182M $260M FY18 FY19 FY20 FY21 FY22 FY23 Peak ~$1B Projected Cumulative Revenues (2020-2022)
AT-GAA: Next Potential Standard of Care for Pompe Disease “We encourage and embrace constant innovation” - Amicus Belief Statement
AT-GAA for Pompe Disease 11 U.S. FDA Granted BTD to AT-GAA in Late-Onset Pompe Disease (LOPD) AT-GAA is the first ever second-generation product for any lysosomal disorder to earn FDA Breakthrough Therapy Designation (BTD) AT-GAA BTD Based on Ph 1/2 Clinical Efficacy • Improvements in 6-minute walk distance Plans to apply for and • Comparison to natural history of treated patients initiate a rolling BLA submission for AT-GAA in LOPD in 2020 BTD Features • Intensive guidance on an efficient drug development program • Organizational commitment involving senior agency staff • All Fast Track program features including rolling submission BTD Criteria • Intended to treat a serious or life-threatening disease or condition • Preliminary clinical evidence indicates drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints
AT-GAA for Pompe Disease 12 AT-GAA: Key Takeaways • PROPEL pivotal study exceeded enrollment with data expected 1H2021 • Breakthrough Therapy Designation and the Promising Innovative Medicine designation highlight unmet need in AT-GAA for Pompe Pompe disease today Advances Toward • Plan to submit and initiate rolling submission of Biologics Approval as “Crown License Application in 2020 Jewel” of Amicus Portfolio • Manufacturing PPQ runs at WuXi biologics on track • Peak revenue potential of $1B-$2B, with exclusivity well into 2030s
Financial Summary “We are business led and science driven” - Amicus Belief Statement
Financial Summary 14 2019 Select Financial Results 2019 revenue of $182M from global Galafold sales Dec. 31, 2019 (in thousands, except per share data) Dec. 31, 2018 Product Revenue $182,237 $91,245 Cost of Goods Sold 21,963 14,404 R&D Expense* 286,378 270,902 SG&A Expense 169,861 127,200 Changes in Fair Value of Contingent Consideration 3,297 3,300 Depreciation and Amortization 4,775 4,216 Loss from Operations (304,037) (328,777) Income Tax (Expense) Benefit (478) 94 Net Loss (356,388) (348,995) Net Loss Per Share (1.48) (1.88) *Inclusive of the 2018 upfront payment of $100 million for the Celenex asst acquisition.
Financial Summary 15 Cash Runway Now to Well into 2022 (~2+ years) Fully funded through major milestones in portfolio and continued global growth $450M+ Well into Cash ~2+ Years Cash Runway 2022 YE2019
Financial Summary 16 Financial Outlook: Key Takeaways • Company fully funded through major milestones in portfolio and continued global growth • Cumulative Galafold projected revenue of $1B+ in 2020-2022 offsets significant majority of company spend/investments • Extended cash flow runway through OpEx savings, CapEx phasing, program prioritization and increased Galafold revenue projections • No material business development planned or needed in next several years • Only modest additional capital required in the outer years to extend runway into profitability with multiple non-equity sources available as/when needed
Next Generation Gene Therapy Platform “We have a duty to obsolete our own technologies” - Amicus Belief Statement
Next Generation Gene Therapy Platform 18 DISCOVERY PRECLINICAL PHASE 1/2 PHASE 3 REGULATORY COMMERCIAL Fabry Franchise Galafold®(migalastat) Monotherapy ODD Fabry Gene Therapy PENN Pompe Franchise AT-GAA (Novel ERT + Chaperone) ODD Pompe Gene Therapy PENN Batten Franchise – Gene Therapies CLN6 Batten Disease ODD RPD NCH CLN3 Batten Disease ODD RPD NCH CLN8 Batten Disease NCH CLN1 Batten Disease NCH Next Generation Research Programs and CNS Gene Therapies CDKL5 Deficiency Disorder GTx / ERT PENN Niemann-Pick Type C (NPC) NCH / PENN Others NCH / PENN MPS Franchise LEGEND Mepsevii™ (vestronidase alfa) (Japan Only)* ODD - Orphan Drug Designation Next Generation MPSIIIA PENN RPD - Rare Pediatric Disease Designation MPSIIIB PENN *Exclusive license from Ultragenyx for Japanese rights to Mepsevii™, investigator-sponsored trial in Japan underway
Next Generation Gene Therapy Platform 19 Combines Amicus and Penn Expertise Across Lysosomal and Rare Diseases An R&D platform with rights to 50+ diseases, including 8 active preclinical programs Protein Team of 200+ Engineering & scientists bringing Glycobiology expertise and Expertise Next- experience in: Clinical and Vectors, Tropisms, Generation Capsids Regulatory Expertise Gene Therapy Safety Dosing, Global Commercial Platform Immunology Infrastructure Manufacturing, Scalability Driving 1-2 new INDs every year starting in 2020
Next Generation Gene Therapy Platform 20 Gene Therapy: Updates & Key Takeaways • CLN6 Phase 1/2 interim data shows profound impact with potential to become first ever approved gene therapy for fatal brain disease in children • Plan to report initial data for patients enrolled in CLN3 Phase 1/2 Portfolio of Gene study in 2H’20 Therapy Programs • Orphan drug designations granted in U.S. and EU for intrathecal and Technologies AAV gene therapies for CLN6 and CLN3 Batten disease. Provides Foundation for Future • Pompe gene therapy moving into IND-enabling studies • Penn Collaboration is R&D engine, with rights to 50+ diseases • 8 preclinical gene therapies in development
Closing Remarks “We are business led and science driven” - Amicus Belief Statement
Thank You “Our passion for making a difference unites us” -Amicus Belief Statement
Appendix
Appendix 24 Non-GAAP Reconciliation